Protein kinase inhibitors

1. A compound having the following structure (I):

or a pharmaceutically acceptable salt thereof, wherein

R 1 is structure (a), (b), (c) or (d):

R a and R b are independently hydrogen, halogen, alkyl, aryl, heterocycle, —CN, —NO 2 , —OR, —SR, —NRR, —C(═O)R —C(═O)OR, —NHC(═O)OR, or —SO 2 NRR; and R c is hydrogen, alkyl, —S(O)R or —(SO 2 )R;

R is, at each occurrence, independently hydrogen, alkyl, or aryl;

R 2 is hydrogen or alkyl;

R 3 is optionally substituted aryl or optionally substituted heterocycle;

R 4 is hydrogen or alkyl;

R 5 is hydrogen or lower alkyl; and

R 6 and R 7 are independently hydrogen, halogen, cyano, lower alkyl, aryl or heterocycle.

2. The compound of claim 1 wherein R 1 is structure (a), and the compound has the following structure (II):

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 wherein R 1 is structure (b), and the compound has the following structure (III):

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 wherein R 1 is structure (c), and the compound has the following structure (IV):

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 wherein R 1 is structure (d), and the compound has the following structure (V):

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 2 wherein R a , R c , R 2 , R 4 , R 5 and R 6 are hydrogen, and the compound has the following structure (VI):

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 3 wherein R a , R c , R 2 , R 4 , R 5 and R 6 are hydrogen, and the compound has the following structure (VII):

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 4 wherein R a , R c , R 2 , R 4 , R 5 and R 6 are hydrogen, and the compound has the following structure (VIII):

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 5 wherein R a , R c , R 2 , R 4 , R 5 and R 6 are hydrogen, and the compound has the following structure (IX):

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 wherein R 3 is an optionally substituted phenyl group, and the compound has the following structure (X):

or a pharmaceutically acceptable salt thereof, wherein

R 3a , R 3b and R 3c are independently hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocycle, —COOR 8 , —COR 8 , —CONR 8 2 , —NR 8 C(═O)R 8 , —NR 8 COOR 8 , —OR 8 , —SO n R 8 , —SO n NR 8 2 , —NR 8 S(O) n R 8 , and —SO n R 9 , wherein

R 8 is, at each occurrence, independently hydrogen or an optionally substituted alkyl group;

R 9 is an optionally substituted heterocycle group; and

n is 0, 1 or 2; or

any two of R 3a , R 3b and R 3c when attached to adjacent atoms of the phenyl group are taken together with the carbon atoms to which they are attached to form an optionally substituted fused heterocylic ring, or an optionally substituted fused carbocyclic ring.

11. The compound of claim 10 wherein at least one of R 3a , R 3b and R 3c is:

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 10 wherein R 3b and R 3c are attached to adjacent atoms of the phenyl group and taken together with the carbon atoms to which they are attached to form an optionally substituted, fused heterocylic ring, or an optionally substituted, fused carbocyclic ring, and the compound has one the following structures (XI) or (XII):

or a pharmaceutically acceptable salt thereof, wherein

A is an optionally substituted heterocyclic ring or an optionally substituted carbocyclic ring.

13. The compound of claim 12 wherein the group

has the structure:

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 wherein R 3 is an optionally substituted heterocycle group, and the compound has the following structure (XIII):

or a pharmaceutically acceptable salt thereof, wherein

B is the optionally substituted heterocycle group.

15. The compound of claim 14 wherein B is an optionally substituted pyridine group or an optionally substituted pyrimidine group.

16. The compound of claim 1 wherein the compound is: 1-(4-(4-(4-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, N4-(1H-indazol-6-yl)-N2-(4-(piperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, 1-(4-(4-(4-(3-methyl-1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, N4-(3-methyl-1H-indazol-6-yl)-N2-(4-(piperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, 6,6′-(7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(azanediyl)bis(2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one, N2,N4-di(1H-indazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, N 4 -(1H-benzo[d]imidazol-6-ylamino)-N 2 -(1H-indazoyl-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2,4-diamine, N-(4-(4-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)-N-methylacetamide, 1-(4-(4-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperidin-4-ol, N4-(1H-indazol-6-yl)-N2-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-(1-(methylsulfonyl)-1H-indazol-6-yl)-N2-(4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-(1H-indazol-6-yl)-N2-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-(1H-indazol-6-yl)-N2-(4-(methylsulfinyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-(1H-indazol-6-yl)-N2-(4-(methylthio)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, 4-(4-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzenesulfonamide, 4-(4-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, N4-(1H-indazol-6-yl)-N2-(4-(4-methylpiperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, 1-(4-(4-(4-(1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone and N4-(1H-indazol-5-yl)-N2-(4-(piperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, 1-(4-(4-(4-(1H-indazol-6-ylamino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, 6-(2-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one, N-(4-(4-(4-(4-(H-benzo[d]imidazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylaminophenyl)-N-methylacetamide, 1-(4-(4-(1H-benzo[d]imidazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylaminophenyl)-N,N-dimethylpiperidine-4-carboxamide, N4-(benzo[d]thiazol-5-yl)-N2-(1H-indazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, N4-(benzo[d]thiazol-6-yl)-N2-(1H-indazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine or 1-(4-(4-(4-(1H-indazol-6-ylamino)-5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, N4-(1-methyl-1H-indazol-6-yl)-N2-(4-(piperazin-1-yl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, 1-(4-(4-(4-(1-methyl-1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, 4-(4-(1-methyl-1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 6-(4-(1-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one, 4-(4-(1-methyl-1H-indazol-5-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 4-(4-(1H-indazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)benzamide, 1-(4-(4-(4-(1H-indazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, or a pharmaceutically acceptable salt thereof.

17. A composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.